Life sciences group Abzena (ABZA:AIM) has sealed a licensing agreement with the potential to generate $300m in licence fees and milestone payments. That compares to the £9.85m of revenue chalked up last year, to 31 March 2016.

Having struck the deal with an undisclosed San Diego-based biopharma firm, Abzena is set to receive royalties on sales of approved products that use its ThioBridge technology, the second major licensing deal for the platform in a year.

ThioBridge allows drugs to be attached to antibodies that can be then specifically targeted at various diseases. Abzena also signed a master services agreement to allow multiple programmes of work to be undertaken over an extended period.

The deal caused wild reactions from investors, with the share price rocketing a staggering 72% to 61.5p.

Abzena graph jan

Broker Numis analyst Stefan Hamill says the $300m deal will underpin Abzena’s near, mid and long-term revenue.

Still, investors should remember the drug development cycle is a long process with high failure rates, so potential licence income is not guaranteed.

But N+1 Singer analyst Jens Lindqvist remains upbeat. He believes the life science group’s share price could even rally further if it can maximise its opportunity pipeline.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Issue Date: 20 Jan 2017